Hemophagocytic Lymphohistiocytosis-Like Toxicity (carHLH) after CD19-Specific CAR T-cell Therapy

Researchers reported the development of carHLH in 14·8% of paediatric patients and young adults treated with CD19-specific CAR T-cell therapy with carHLH, occurring most commonly in those with high disease burden.